Document is current
Any future updates will be listed below
-
Authors
Li, Yuying
Pan, Meijie
Yu, Haonan
Zhang, Qilei
Chang, Yan
Zhao, Hailong
Wang, Jiaqi
Wang, Xiaoming
Dai, Jiapei
Yu, Lu
Chen, Dong
Zhang, Jinming
Yan, Xiao-xin
Yao, Shaobo
Cui, Mengchao https://orcid.org/0000-0002-3488-7864
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (22306015)
National Natural Science Foundation of China (22376016)
National Natural Science Foundation of China (22022601)
Science Innovation 2030-Brain Science and Brain-Inspired Intelligence Technology Major Projects (2021ZD0201103)
Science Innovation 2030-Brain Science and Brain-Inspired Intelligence Technology Major Projects (2021ZD0201803)
- License Information
-
More Information
Article History
Received: 9 September 2025
Accepted: 9 December 2025
First Online: 10 January 2026
Declarations
:
: All animal procedures complied with institutional and national guidelines and were approved by the Animal Care and Use Committee of Beijing Normal University (BNUCC-EAW-2023-0615-01). Healthy volunteers were enrolled in a phase I clinical trial of [ 18 F]Florbetazine conducted in China, All PET/CT imaging procedures were performed in accordance with the principles approved by the ethics committee of the Chinese PLA General Hospital. The trial is registered at ClinicalTrials.gov (NCT06593626). A patient with biopsy-confirmed amyloidosis underwent [ 18 F]Florbetazine PET/CT imaging under a protocol approved by the Clinical Research Ethics Committee of the General Hospital of Tianjin Medical University, and the trail is registered at ClinicalTrials.gov (NCT06725706).
: All reported subjects provided written informed consent to participate in the clinical study and for the publication of their anonymized case details and medical data.
: The authors declare no competing financial interest.
